2016
DOI: 10.1002/rcr2.151
|View full text |Cite|
|
Sign up to set email alerts
|

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer

Abstract: Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non‐small cell lung cancer. There are few reports describing bevacizumab‐induced chronic interstitial pneumonia.A 62‐year‐old man with advanced non‐small cell lung cancer was admitted to our hospital with dyspnea. He previously received four courses of carboplatin plus paclitaxel with bevacizumab combination therapy and thereafter received four courses of maintenance bevacizumab monotherap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 6 publications
0
4
0
Order By: Relevance
“…In 37 MAC lung disease subjects, those with neutrophil-dominant BAL had more severe radiographic disease and greater clinical deterioration than those with lymphocyte-dominant BAL (180) Associated with development of hemoptysis, pulmonary embolus, pulmonary hemorrhage and interstitial pneumonitis (189). With interstitial pneumonitis, BAL may reveal elevated lymphocytes (190) Bleomycin Neutrophilia from limited data (191) Bortezomib (proteasome inhibitor)…”
Section: Pneumocystis Jirovecii Pneumonia (Pjp) or Pcp Pneumoniamentioning
confidence: 99%
“…In 37 MAC lung disease subjects, those with neutrophil-dominant BAL had more severe radiographic disease and greater clinical deterioration than those with lymphocyte-dominant BAL (180) Associated with development of hemoptysis, pulmonary embolus, pulmonary hemorrhage and interstitial pneumonitis (189). With interstitial pneumonitis, BAL may reveal elevated lymphocytes (190) Bleomycin Neutrophilia from limited data (191) Bortezomib (proteasome inhibitor)…”
Section: Pneumocystis Jirovecii Pneumonia (Pjp) or Pcp Pneumoniamentioning
confidence: 99%
“…Bevacizumab is a monoclonal antibody that inhibits the activity of the vascular endothelial growth factor receptor, and it is indicated in the treatment of metastatic breast cancer, metastatic rectal carcinoma, and advanced lung cancer. Recently, the first case of interstitial disease has been described during maintenance therapy with bevacizumab in a patient with lung carcinoma [35]. Trastuzumab is a monoclonal antibody that binds the HER-2 receptor and it is prescribed in the treatment of advanced and metastatic breast carcinoma.…”
Section: Anti-inflammatory and Immunomodulators Drugsmentioning
confidence: 99%
“…Usui et al demonstrated a higher incidence of pneumonitis in patients with colorectal cancer who were treated with conventional cytotoxic chemotherapeutic drugs plus bevacizumab (BEV), another VEGF inhibitor, than in those who did not receive BEV [ 21 ]. Furthermore, Sekimoto et al reported a patient with NSCLC who was treated with a combination of carboplatin, PTX, and BEV [ 22 ]. The combination of a VEGF inhibitor with a cytotoxic anti-tumor drug may have an impact on the onset of treatment-related pneumonitis.…”
Section: Discussionmentioning
confidence: 99%